VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events

VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On August 28, 2017, VBI Vaccines Inc. (the “Company”) issued a press release announcing that David Anderson, Ph.D., the Company’s Chief Scientific Officer, will present new preclinical data demonstrating the mechanism by which VBI-1901 stimulates CMV-specific immunity in monkeys at the Immuno-Oncology Summit in Boston on August 30, 2017. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description
99.1 Press Release dated August 28, 2017


VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm     VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy,…
To view the full exhibit click here

About VBI VACCINES INC. (TSE:VBV)

VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).

An ad to help with our costs